Tafamidis Aminopyridine Smiles: CC1N=CSC=1C1=CC=C(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCNC(=O)C2C=CC(=CC=2)C2=CN=C(NCC3=CC=CO3)N3C=NN=C32)C(C)(C)C)C=C1

Smiles: CC1N=CSC=1C1=CC=C(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCNC(=O)C2C=CC(=CC=2)C2=CN=C(NCC3=CC=CO3)N3C=NN=C32)C(C)(C)C)C=C1

is a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth

5-dioxo-2H

A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist

Tafamidis Aminopyridine Smiles: CC1N=CSC=1C1=CC=C(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCNC(=O)C2C=CC(=CC=2)C2=CN=C(NCC3=CC=CO3)N3C=NN=C32)C(C)(C)C)C=C1Tafamidis, Tafamidis, also known as Fx 1006 or PF 06291826, is a drug for the amelioration of transthyretin related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded